Table 1 Baseline characteristics of the study groups
Ulcerative colitis | Crohn's disease | |||
|---|---|---|---|---|
Lactulose (n= 7) | Control (n= 7) | Lactulose (n= 9) | Control (n= 8) | |
Age* | 38.8 ± 12.4 | 38.1 ± 8.8 | 30.7 ± 7.0 | 33.5 ± 11.7 |
Female sex | 3 | 4 | 5 | 4 |
Disease duration (years)* | 8.3 ± 12.2 | 9.3 ± 5.0 | 5.0 ± 5.4 | 6.7 ± 9.8 |
Disease Activity (CAI/CDAI)* | 10.3 ± 5.9 | 10.4 ± 11.2 | 195.5 ± 148.4 | 273.9 ± 112.9 |
IBDQ* | 123 ± 47.0 | 132 ± 58.4 | 136 ± 42.7 | 134 ± 43.3 |
Defecation/week* | 37 ± 24.3 | 36 ± 24.1 | 39 ± 30.4 | 45 ± 23.3 |
Duration of participation* | 3.7 ± 1.5 | 4.8 ± 2.5 | 5.0 ± 3.1 | 4.3 ± 2.2 |
Medication | ||||
Prednisolone equivalents > 5 mg | 5 | 2 | 6 | 6 |
Prednisolone equivalents ≤ 5 mg | 0 | 0 | 1 | 3 |
5-ASA | 7 | 4 | 6 | 3 |
Immunosuppressive drugs | 1 | 1 | 3 | 2 |
Antibiotics | 0 | 3 | 5 | 4 |